Completed PHASE3 INTERVENTIONAL NCT00394121

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma

Sponsor: SkyePharma AG

Conditions Asthma

Interventions Fluticasone propionate/formoterol fumarate

Updated 8 times since 2017 Last updated: Aug 24, 2010 Started: Mar 31, 2006 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00394121, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by SkyePharma AG, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Feb 2026 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SkyePharma AG

Data source: SkyePharma AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bialystok, Poland , Birmingham, United Kingdom , Bucharest, Romania , Budapest, Hungary , Carrickfergus, United Kingdom , Chippenham, United Kingdom , Cottingham, United Kingdom , Coventry, United Kingdom , Deszk, Hungary and 18 more locations